Ovid Therapeutics (OVID) Debt Ratio (2019 - 2020)
Ovid Therapeutics (OVID) posted Debt Ratio of 0.03 for Q4 2020, up 919.78% on a QoQ basis from 0.0 in Q3 2020, and up 770.89% year-over-year from 0.0 in Q1 2020.
Ovid Therapeutics (OVID) Debt Ratio (2019 - 2020) Analysis & Trends
Ovid Therapeutics' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.03 for Q4 2020.
- Quarterly Debt Ratio rose 770.89% year-over-year to 0.03 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was 0.03 (up 770.89% YoY) and the FY2020 annual result came in at 0.03, up 770.89% from the prior year.
- Debt Ratio was 0.03 for Q4 2020 at Ovid Therapeutics, up from 0.0 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.03 in Q4 2020 and bottomed at 0.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | 1.41 |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | 0.11 |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | - |
| 10 | Ovid Therapeutics | 120.91 Mn | -34.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 0.03 |
| Sep 30, 2020 | 0.00 |
| Jun 30, 2020 | 0.01 |
| Mar 31, 2020 | 0.00 |
| Dec 31, 2019 | 0.00 |
| Sep 30, 2019 | 0.02 |
| Jun 30, 2019 | 0.02 |
| Mar 31, 2019 | 0.02 |